Electroconvulsive seizures regulate various stages of hippocampal cell genesis and mBDNF at different times after treatment in adolescent and adult rats of both sexes DOI Creative Commons
Sandra Ledesma‐Corvi, M. Julia García‐Fuster

Frontiers in Molecular Neuroscience, Journal Year: 2023, Volume and Issue: 16

Published: Oct. 30, 2023

Electroconvulsive therapy, a fast-acting option for treatment-resistant depression, is modeled at the preclinical level through induction of electroconvulsive seizures (ECS) in rodents. Recent studies from our group proved sex- and age-differences antidepressant-like response elicited by ECS rats; while an was observed male adolescent adult rats (although with greater efficacy adulthood), same parameters rendered inefficacious females any age. To better understand potential sex differences taking place molecular that might be mediating these behavioral disparities, we evaluated impact repeated treatment (95 mA 0.6 s, 100 Hz, ms) both sexes. Several hippocampal markers neuroplasticity, commonly regulated most antidepressants, such as those neurogenesis (cell proliferation, neurogenic differentiation, long-term cell survival) or mBDNF associated signaling (e.g., mTOR ERK1/2) were different time-points after (1-, 8-, 15- up to 30-days post-treatment). The main results demonstrated improved survival rate new cells born dentate gryus before treatment. Moreover, increased proliferation differentiation times post-treatment, paired persistent increases mBDNF, long In general, effects each varied age animal (adolescent vs. adulthood). present study first-one demonstrate changes induced hippocampus, some them also occurred female adolescence. Although could not justify lack described (vs. rats), they proposed certain beneficial common sexes, periods studied, opening avenue further studies. Based on neurochemical effects, should have displayed similar efficacies biological Therefore, reason behind disparities explored translate efficacious treatments specific and/or personalized clinic.

Language: Английский

Advances in the Study of NMDA Receptors in Depression Pathogenesis and the Antidepressant Efficacy of Their Antagonists DOI
Mingrui Chen,

Jingyan Jin,

Hongsheng Bi

et al.

Asian Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 108, P. 104502 - 104502

Published: April 19, 2025

Language: Английский

Citations

0
The Importance of α-Klotho in Depression and Cognitive Impairment and Its Connection to Glutamate Neurotransmission—An Up-to-Date Review DOI Open Access
Patrycja Pańczyszyn-Trzewik, Ewelina Czechowska, Katarzyna Stachowicz

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(20), P. 15268 - 15268

Published: Oct. 17, 2023

Depression is a serious neuropsychiatric disease affecting an increasing number of people worldwide. Cognitive deficits (including inattention, poor memory, and decision-making difficulties) are common in the clinical picture depression. impairment has been hypothesized to be one most important components major depressive disorder (MDD; referred as depression), although typical cognitive symptoms less frequent with depression than schizophrenia or bipolar (BD; sometimes manic-depressive disorder). The importance α-Klotho aging process well-documented. Growing evidence points role regulating other biological functions, including responses oxidative stress modulation synaptic plasticity. It proven that Klotho deficit may contribute development various nervous system pathologies, such behavioral disorders neurodegeneration. Given growing impairment, it assumed this protein molecular link between them. Here, we provide research review impairment. Furthermore, propose potential mechanisms (related glutamatergic transmission) α-Klotho-mediated regulation mental function.

Language: Английский

Citations

10
Effect of oral tryptamines on the gut microbiome of rats—a preliminary study DOI Creative Commons
Mengyang Xu, Andor J. Kiss, J. Andrew Jones

et al.

PeerJ, Journal Year: 2024, Volume and Issue: 12, P. e17517 - e17517

Published: June 3, 2024

Background Psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. Research on mechanisms of these effects has historically focused direct drugs neural processes. However, addition to such effects, alterations peripheral physiology may also contribute their therapeutic effects. In particular, substantial support exists a gut microbiome-mediated pathway antidepressant efficacy other drug classes, but no prior studies determined microbiota. Methods To address this gap, preliminary study, male Long Evans rats were treated with varying dosages oral psilocybin (0.2 or 2 mg/kg), norbaeocystin (0.25 2.52 vehicle fecal samples collected 1 week 3 weeks after exposure microbiome analysis using integrated 16S ribosomal DNA sequencing determine composition. Results We found that although treatment neither nor significantly affected overall diversity, it did cause significant dose- time-dependent changes bacterial abundance at phylum level, including increases Verrucomicrobia Actinobacteria , decreases Proteobacteria . Conclusion Implications These findings idea act manner, potentially identifying novel mechanism activity. The results from study suggest warrant further investigation antidepressant, given similarity its psilocybin.

Language: Английский

Citations

3
Design, synthesis, and antitumor activity evaluation of BF3-o, m, p-phenylenediamine bridged with pyrimidine-indole BF3 adduction derivatives DOI
Meng Zhou,

Xiujie Duan,

Tao Jin

et al.

Molecular Diversity, Journal Year: 2024, Volume and Issue: 29(1), P. 425 - 437

Published: July 19, 2024

Language: Английский

Citations

3
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review DOI Creative Commons
Giulia Menculini,

Gianmarco Cinesi,

Francesca Scopetta

et al.

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15

Published: July 11, 2024

Major depressive disorder (MDD) represents a major health issue in adolescents and young adults, leading to high levels of disability profoundly impacting overall functioning. The clinical presentation MDD this vulnerable age group may slightly differ from what can be observed adult populations, psychopharmacological strategies do not always lead optimal response. Resistance antidepressant treatment has prevalence estimated around 40% youths suffering is associated with higher comorbidity rates suicidality. Several factors, encompassing biological, environmental, features, contribute the emergence treatment-resistant depression (TRD) adults. Furthermore, TRD underpin presence an unrecognized bipolar diathesis, increasing complexity picture posing differential diagnosis challenges practice. After summarizing current evidence on epidemiological correlates present review also provides overview possible strategies, including novel fast-acting antidepressants. Despite these pharmacological agents are promising population, their usage expected rely risk-benefit ratio considered context integrated models care.

Language: Английский

Citations

2
LT-102, an AMPA receptor potentiator, alleviates depression-like behavior and synaptic plasticity impairments in prefrontal cortex induced by sleep deprivation DOI
Yanghao Zheng, Xueli Yu,

Wei Long

et al.

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: 367, P. 18 - 30

Published: Aug. 29, 2024

Language: Английский

Citations

1
Adenosine A2A signaling in mood disorders: how far have we come? DOI Creative Commons
Laura Menegatti Bevilacqua,

Francisco da Silveira Neto,

Manuella P. Kaster

et al.

IBRO Neuroscience Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

1
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential DOI Creative Commons
Robert B. Kargbo

ACS Medicinal Chemistry Letters, Journal Year: 2023, Volume and Issue: 14(10), P. 1331 - 1333

Published: Sept. 15, 2023

Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA treatment-resistant depression, major depressive disorder, post-traumatic stress sparking global research efforts. Various clinical trials are currently investigating therapeutic value several disorders. Results thus far indicate significant improvements in patient-reported outcomes via reductions experiential avoidance. These advancements highlight promising future tryptamines therapy.

Language: Английский

Citations

2
Natural L-type calcium channels antagonists from Chinese medicine DOI Creative Commons
Fangfang Xu,

Wanna Cai,

Бо Лю

et al.

Chinese Medicine, Journal Year: 2024, Volume and Issue: 19(1)

Published: May 21, 2024

Abstract L-type calcium channels (LTCCs), the largest subfamily of voltage-gated (VGCCs), are main for Ca 2+ influx during extracellular excitation. LTCCs widely present in excitable cells, especially cardiac and cardiovascular smooth muscle participate various -dependent processes. have been considered as worthy drug target cardiovascular, neurological psychological diseases decades. Natural products from Traditional Chinese medicine (TCM) shown potential new drugs treatment related diseases. In this review, basic structure, function LTCCs, human caused by structural or functional abnormalities natural antagonist their usages were summarized.

Language: Английский

Citations

0
Network Pharmacology and Transcriptomics to Explore the Pharmacological Mechanisms of 20(S)-Protopanaxatriol in the Treatment of Depression DOI Open Access

Xiangjuan Guo,

Lili Su,

Meiling Shi

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7574 - 7574

Published: July 10, 2024

Depression is one of the most common psychological disorders nowadays. Studies have shown that 20(S)-protopanaxatriol (PPT) can effectively improve depressive symptoms in mice. However, its mechanism needs to be further explored. In this study, we used an integrated approach combining network pharmacology and transcriptomics explore potential mechanisms PPT for depression. First, targets pathways treatment depression were screened through pharmacology. Secondly, BMKCloud platform was obtain brain tissue transcription data chronic unpredictable mild stress (CUMS) model mice screen PPT-altered differential expression genes (DEGs). Gene ontology (GO) analysis Kyoto Encyclopedia Genes Genomes (KEGG) performed using transcriptomics. Finally, above results verified by molecular docking, Western blotting, quantitative real-time polymerase chain reaction (qRT-PCR). demonstrated improved depression-like behavior histopathological changes CUMS mice, downregulated nitric oxide (NO) interleukin-6 (IL-6) levels, elevated serum levels 5-hydroxytryptamine (5-HT) brain-derived neurotrophic factor (BDNF) after compared group. Eighty-seven 350 DEGs identified Comprehensive showed transthyretin (TTR), klotho (KL), FOS, phosphatidylinositol 3-kinase–protein kinase B (PI3K-AKT) signaling pathway closely associated with therapeutic effects PPT. Molecular docking had a high affinity PI3K, AKT, TTR, KL, FOS targets. protein level could increase phosphorylation PI3K (p-PI3K), AKT (p-AKT), KL inhibit depressed Our suggest may achieve inhibiting enhancing TTR modulating PI3K-AKT pathway.

Language: Английский

Citations

0